GHRP-6 holds a foundational position in the peptide research literature as the original synthetic growth hormone secretagogue. First characterized by Cyril Bowers and colleagues in 1984, it predates the discovery of ghrelin by 15 years and provided the pharmacological template from which the entire GHRP/GHS compound class was developed. Despite newer and more selective secretagogues such as ipamorelin and GHRP-2 largely superseding it in GH axis research protocols, GHRP-6 retains unique research utility — particularly in gastric motility studies, appetite regulation models, and investigations of the orexigenic arm of GHSR-1a signaling.
This guide covers GHRP-6's structure, pharmacological history, GHSR-1a binding affinity, GH release data, cortisol and ACTH activation profile, appetite stimulation mechanism, gastroprotective research utility, synergy with GHRH analogs, desensitization kinetics, and preclinical dosing considerations.
Discovery and Historical Significance
GHRP-6 was synthesized by Bowers et al. at Tulane University as part of a program to identify met-enkephalin analogs capable of stimulating GH release. The resulting hexapeptide — His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ — was found to potently stimulate GH secretion in rats via a receptor distinct from the GHRH receptor. This finding was initially puzzling: the compound acted synergistically with GHRH but through an independent pathway.
The orphan receptor responsible for GHRP-6's effects was identified in 1996 by Howard et al. (Science) as the growth hormone secretagogue receptor type 1a (GHSR-1a). In 1999, Kojima et al. (Nature) identified the endogenous ligand for GHSR-1a as ghrelin — an acylated 28-amino-acid peptide from the gastric fundus. This retroactively established GHRP-6 as the first characterized synthetic ghrelin mimetic, 15 years before ghrelin's discovery. The GHRP scaffold directly informed structural understanding of GHSR-1a's binding pocket and remains a reference scaffold for the class.
Structure and Receptor Pharmacology
GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. The D-Trp at position 2 provides proteolytic resistance and the conformational rigidity required for GHSR-1a binding; the C-terminal Lys-NH₂ contributes hydrophobic receptor contact. It shares near-identical primary sequence with GHRP-2 — the critical structural distinction being that GHRP-2 lacks GHRP-6's C-terminal lysine extension and contains a slightly different stereochemical arrangement that modestly increases GHSR-1a affinity.
GHRP-6 binds GHSR-1a with an affinity (Ki) of approximately 2.0–3.5 nM in radioligand displacement assays — lower than GHRP-2 (0.8–1.2 nM) and hexarelin (0.3–0.5 nM), but comparable to native ghrelin (1.5–2.0 nM). GHSR-1a is a Gq/11-coupled class A GPCR. Activation by GHRP-6 triggers PLC-beta/IP₃/DAG signaling, elevating intracellular calcium in somatotroph cells and driving GH granule exocytosis. At the hypothalamus, GHSR-1a activation additionally suppresses somatostatin tone, amplifying pituitary GH release.
GH Release Data and Potency Profile
In healthy human subjects, IV GHRP-6 at 1 mcg/kg produces mean peak GH responses of 40–60 ng/mL at 15–30 minutes post-injection. Bowers 1990 (JCEM) reported mean GH peaks of approximately 45–55 ng/mL at 1 mcg/kg IV, with dose-response saturation occurring at approximately 2 mcg/kg. This places GHRP-6 behind both GHRP-2 (50–70 ng/mL) and hexarelin (70–90 ng/mL) in peak GH amplitude, but ahead of ipamorelin (~25–35 ng/mL at equivalent doses) — reflecting its moderate GHSR-1a affinity.
Subcutaneous administration yields 40–50% lower peak GH than IV equivalents, with a delayed Tmax of 30–45 minutes. The GH pulse duration from SC GHRP-6 spans approximately 2–3 hours, similar to other hexapeptide GHRPs. In rodent models, IP administration at 80–160 mcg/kg produces robust GH pulses within 15–30 minutes, with IGF-1 elevation of 25–45% detectable at 6–8 weeks of daily dosing.
Cortisol and ACTH Activation
Like GHRP-2 and hexarelin, GHRP-6 activates the hypothalamic-pituitary-adrenal (HPA) axis via central GHSR-1a receptors in the paraventricular nucleus (PVN), stimulating CRH and AVP release, which drives anterior pituitary ACTH secretion and adrenal cortisol output. At standard research doses (1–2 mcg/kg), GHRP-6 typically elevates cortisol by 1.5–2.0× baseline and ACTH by 2–3× baseline at 30–60 minutes post-injection.
This HPA activation profile is comparable to GHRP-2 and substantially greater than ipamorelin (which shows minimal cortisol/ACTH effects at equivalent GH-releasing doses). Researchers designing GH axis protocols where HPA confounding is a concern should account for this elevation in cortisol, particularly in rodent stress behavior or metabolic studies where glucocorticoid tone influences insulin sensitivity and body composition endpoints.
Orexigenic Appetite Stimulation: The GHRP-6 Signature Effect
GHRP-6's most pharmacologically distinctive feature — and the primary reason it remains uniquely useful relative to newer, more selective GHRPs — is its strong orexigenic (appetite-stimulating) activity. This property mirrors ghrelin's established role as an endogenous hunger signal and stems from GHSR-1a activation in the arcuate nucleus of the hypothalamus.
GHSR-1a-expressing neurons in the arcuate nucleus co-express neuropeptide Y (NPY) and agouti-related protein (AgRP), two potent orexigenic neuropeptides. GHRP-6 stimulation of these neurons elevates NPY and AgRP mRNA expression, increases NPY/AgRP peptide release into the paraventricular nucleus and lateral hypothalamic area, and drives food intake behavior. Studies in rodents demonstrate that IP GHRP-6 at 50–200 mcg/kg acutely increases food intake by 30–80% within 1–2 hours of injection, with a dose-dependent relationship.
Gastric motility effects complement this central hunger signal: GHSR-1a activation in the vagal-gastric axis accelerates gastric emptying and reduces gastric acid secretion latency, contributing to the perceived hunger state. GHRP-6 induces significantly stronger appetite stimulation than GHRP-2 (which shows intermediate hunger effects) or ipamorelin (which shows minimal orexigenic activity), making it the preferred choice for research specifically investigating the ghrelin-hunger axis.
Gastroprotective Research Data
GHRP-6 has demonstrated notable gastroprotective effects in rodent models of gastric mucosal injury. The mechanism involves GHSR-1a-dependent activation of protective pathways in gastric mucosa cells — including upregulation of prostaglandin E2 synthesis, reduction of oxidative stress via SOD/catalase induction, and attenuation of pro-inflammatory cytokine release (TNF-α, IL-6) in gastric tissue.
In ethanol-induced and indomethacin-induced gastric ulcer models, SC GHRP-6 at 40–120 mcg/kg IP administered 30 minutes prior to mucosal insult significantly reduced ulcer index scores, preserved mucous cell density, and attenuated myeloperoxidase (MPO) activity — a marker of neutrophil infiltration. Gastric emptying studies (Tache et al., 2006) demonstrated that GHRP-6 accelerates gastric emptying in models of gastroparesis, with effects mediated both centrally (vagal GHSR-1a) and peripherally (gastric smooth muscle GHSR-1a). This gastroprotective and prokinetic profile makes GHRP-6 the GHRP of choice for gastroenterological peptide research.
Synergy with GHRH Analogs
Like other GHRPs, GHRP-6 acts synergistically with GHRH analogs (sermorelin, CJC-1295 No DAC, tesamorelin) via complementary mechanisms. GHRH receptor activation drives Gs/cAMP/PKA-mediated GH transcription and granule priming in somatotrophs. GHSR-1a activation by GHRP-6 simultaneously suppresses somatostatin inhibitory tone at the hypothalamus and drives direct Gq/calcium signaling at the pituitary. These complementary pathways produce supraadditive (synergistic) GH release when combined.
Bowers et al. (1998) demonstrated that the combination of GHRH + GHRP-2/GHRP-6 produces GH peaks 6–12× greater than either compound alone at equivalent doses. Similar synergy data exist for CJC-1295 No DAC + GHRP-6 combinations. In preclinical rodent research, combined GHRH/GHRP-6 protocols at sub-maximal doses (e.g., CJC-1295 No DAC at 100 mcg/kg + GHRP-6 at 80 mcg/kg SC) provide substantial GH pulse amplification while allowing dose reduction of each component.
Desensitization and Tachyphylaxis
GHSR-1a undergoes homologous desensitization following repeated GHRP-6 exposure via beta-arrestin-mediated receptor internalization and GRK (G-protein receptor kinase) phosphorylation. Chronic daily GHRP-6 administration in rodent models produces approximately 40–55% attenuation of GH peak response at 4 weeks — similar in magnitude to GHRP-2 (40–55%) and less severe than hexarelin (75–80%). Ipamorelin shows the lowest desensitization rate (~20–30% at 4 weeks), largely attributed to its greater GHSR-1a subtype selectivity and slower GRK activation kinetics.
Importantly, the orexigenic response to GHRP-6 shows a distinct desensitization profile from the GH response — NPY/AgRP-mediated appetite stimulation attenuates more slowly than GH secretion, maintaining a differential pharmacological signature at later timepoints. Washout periods of 4–8 weeks restore GHSR-1a responsiveness to approximately 85–95% of baseline in rodent models.
GHRP-6 vs GHRP-2 vs Ipamorelin: Selecting the Right Compound
The choice between GHRP-6, GHRP-2, and ipamorelin depends on the specific research objective. GHRP-6 is the preferred choice when the research question involves orexigenic signaling, gastric motility, gastroprotection, or the ghrelin-hunger-appetite axis — its strong NPY/AgRP activation is a feature, not a liability, in these contexts. GHRP-2 is preferred when maximizing GH pulse amplitude with moderate cortisol activation is the goal — it achieves higher GH peaks than GHRP-6 at equivalent doses with slightly less appetite stimulation. Ipamorelin is the preferred choice when selective GH stimulation with minimal HPA activation and minimal hunger effects is required — it is the cleanest GHSR-1a agonist for pure GH/IGF-1 axis research.
Preclinical Dosing Protocols
In murine GH axis research, GHRP-6 is typically administered at 80–160 mcg/kg via IP or SC injection. IP administration produces faster Tmax (~15 min) while SC provides a slightly more sustained profile (~30 min Tmax). For GH pulse studies, single-injection protocols at ZT3 or ZT15 (circadian peak and trough of endogenous GH pulse amplitude) allow context-matched GH response assessment. For chronic IGF-1 elevation or body composition studies, once-daily SC injection at 100–150 mcg/kg for 4–12 weeks is the standard model, with IGF-1 measured at weeks 6–8 to capture plateau elevation.
For gastric motility research, IP GHRP-6 at 40–120 mcg/kg administered 30–60 minutes prior to the experimental intervention is standard. For appetite/food intake studies, overnight-fasted animals with ad libitum food access post-injection and 1h, 2h, 4h, and 24h food weight measurements provide the most informative orexigenic time-course data.
For GHRH+GHRP-6 combination protocols, CJC-1295 No DAC (100–200 mcg/kg SC) + GHRP-6 (80–100 mcg/kg SC) administered in the same injection or within 5 minutes provides consistent synergistic GH amplification. A GHSR-1a selective antagonist such as D-[Lys3]-GHRP-6 should be included as a receptor specificity control in mechanistic studies.
Reconstitution and Storage
GHRP-6 is supplied as a lyophilized powder and is reconstituted using bacteriostatic water (0.9% benzyl alcohol). A concentration of 1–2 mg/mL provides convenient dosing volumes for rodent studies. Reconstituted GHRP-6 should be stored at 2–8°C (refrigerated) and used within 2–3 weeks; avoid freeze-thaw cycles with the reconstituted solution, which can promote peptide aggregation. Lyophilized powder is stable at −20°C for 12–24 months if kept dry and protected from light. GHRP-6's linear hexapeptide structure is less prone to disulfide scrambling than cyclic peptides, but standard light and oxidative exposure precautions apply.
Research Design Considerations
Several experimental design points are specific to GHRP-6. (1) Pair-fed controls are particularly important in chronic GHRP-6 studies — the orexigenic effect produces hyperphagia, which independently alters body composition, IGF-1 levels, and metabolic parameters. Without a pair-fed control arm receiving calorie-matched food without GHRP-6, distinguishing GH-mediated from caloric-excess-mediated outcomes is not possible. (2) For HPA confounder assessment, include cortisol/ACTH timepoints at 30–60 min post-injection. (3) In appetitive behavior studies, control for circadian timing — ghrelin/GHSR-1a orexigenic drive peaks in the early dark phase in nocturnal rodents; GHRP-6 injections administered at this timepoint may produce floor effects on appetite stimulation. (4) GHSR-1a receptor selectivity controls (D-[Lys3]-GHRP-6 or JMV2959 at 3–6 mg/kg IP) allow dissection of GHSR-1a-dependent vs independent effects. (5) When investigating GHRP-6's gastroprotective effects, include indomethacin-treated positive controls and assess both macroscopic ulcer index and histological crypt/villus integrity. (6) Sex differences in GHSR-1a expression and ghrelin sensitivity are documented — include both sexes in orexigenic studies with appropriate statistical stratification.
GHRP-6's pharmacological breadth — spanning GH secretion, HPA modulation, orexigenic signaling, and gastroprotection — makes it a versatile but confounded research tool. The key to productive GHRP-6 research is matching the compound to the specific pharmacological question it is uniquely suited to answer, and designing controls adequate to isolate the pathway of interest from its multi-axis signature.